LB Pharmaceuticals Inc Common Stock (LBRX)
Healthcare
Biotechnology
40.10 $
-2.0%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns LB Pharmaceuticals Inc Common Stock (LBRX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 63.1% of the shares are freely tradable; institutional investors hold 106.9%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
106.9%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
0.3%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
63.1%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
18.1%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
29Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Deep Track Capital, LP | 11.69 | 3,352,804 | +0.0 | 03/31/2026 |
| BlackRock Inc | 8.62 | 2,470,845 | +10.4 | 03/31/2026 |
| RA Capital Management, LLC | 7.70 | 2,208,604 | +0.0 | 03/31/2026 |
| TCG Crossover Management, LLC | 6.41 | 1,839,489 | +5.4 | 03/31/2026 |
| COMMODORE CAPITAL LP | 5.23 | 1,500,000 | +0.0 | 03/31/2026 |
| Caligan Partners LP | 5.01 | 1,438,070 | +0.0 | 03/31/2026 |
| JPMorgan Chase & Co | 4.98 | 1,427,568 | -11.4 | 03/31/2026 |
| Spruce Street Capital LP | 4.80 | 1,376,159 | +36.9 | 03/31/2026 |
| Trails Edge Capital Partners, LP | 4.60 | 1,319,362 | -5.5 | 03/31/2026 |
| Vanguard Group Inc | 3.88 | 1,112,978 | +0.0 | 12/31/2025 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.